We implanted 2.5 × 104 B16-F10 melanoma cells on the right and left flanks and treated mice on days 3, 6, and 9 with ODN1826 at 30μg either intra-tumorally or systemically with or without concomitant anti-CTLA-4 (9H10) or anti-PD-1 either locally (10μg) or systemically (100μg/250μg). This evidence concerns the gene PDCD1 and melanoma.